Literature DB >> 30242903

High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis.

Petter Brattström1, Chiara Russo2, David Ley3, Matteo Bruschettini3,4.   

Abstract

AIM: Though caffeine is a consolidated treatment in preterm infants, the efficacy and safety of a higher dose have not been systematically appraised.
METHODS: A systematic review was conducted to compare high (loading dose >20 mg/kg and maintenance >10 mg/kg/day) versus low dose of caffeine. MEDLINE, EMBASE, Central and conference proceedings for randomised controlled trials (RCTs) and quasi-RCTs were searched. Two authors independently screened the records, extracted the data and assessed the risk of bias.
RESULTS: As only six RCTs enrolling a total of 816 preterm infants were included, the required information size was not reached. The loading and maintenance doses varied between 20 and 80 mg/kg/day and 3 and 20 mg/kg/day, respectively. The use of high dose had no impact on mortality (RR: 0.85; 95% CI: 0.53-1.38; RCTs = 4). However, it resulted in fewer cases of extubation failure, apnoeas and bronchopulmonary dysplasia (RR: 0.76; 95% CI: 0.60-0.96; studies = 4) and shorter duration of mechanical ventilation. The quality of the evidence was low due to imprecision of the estimates.
CONCLUSION: Due to imprecision, it is not possible to determine whether high-dose caffeine is more effective and safe than a low dose. High dose might improve short-term respiratory function and reduce bronchopulmonary dysplasia. ©2018 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Cerebral palsy; Dose-response; Evidence-based medicine; Methylxanthine; Optimal information size

Mesh:

Substances:

Year:  2018        PMID: 30242903     DOI: 10.1111/apa.14586

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  8 in total

1.  A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity.

Authors:  Anis Munirah Mohd Kori; Hans Van Rostenberghe; Nor Rosidah Ibrahim; Najib Majdi Yaacob; Ariffin Nasir
Journal:  Int J Environ Res Public Health       Date:  2021-04-23       Impact factor: 3.390

Review 2.  Immature control of breathing and apnea of prematurity: the known and unknown.

Authors:  Grant Erickson; Nicole R Dobson; Carl E Hunt
Journal:  J Perinatol       Date:  2021-03-12       Impact factor: 2.521

Review 3.  Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants.

Authors:  Tobias Muehlbacher; Dirk Bassler; Manuel B Bryant
Journal:  Children (Basel)       Date:  2021-04-13

Review 4.  Oxygen Toxicity to the Immature Lung-Part I: Pathomechanistic Understanding and Preclinical Perspectives.

Authors:  Yesi Choi; Lisa Rekers; Ying Dong; Lena Holzfurtner; Maurizio J Goetz; Tayyab Shahzad; Klaus-Peter Zimmer; Judith Behnke; Jonas Behnke; Saverio Bellusci; Harald Ehrhardt
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

Review 5.  Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Authors:  Rishika P Sakaria; Ramasubbareddy Dhanireddy
Journal:  Front Pediatr       Date:  2022-03-09       Impact factor: 3.418

6.  Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses.

Authors:  Eilan Alhersh; Dina Abushanab; Samaher Al-Shaibi; Daoud Al-Badriyeh
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022

Review 7.  Caffeine and Clinical Outcomes in Premature Neonates.

Authors:  Vasantha H S Kumar; Steven E Lipshultz
Journal:  Children (Basel)       Date:  2019-10-24

Review 8.  Caffeine in preterm infants: where are we in 2020?

Authors:  Laura Moschino; Sanja Zivanovic; Caroline Hartley; Daniele Trevisanuto; Eugenio Baraldi; Charles Christoph Roehr
Journal:  ERJ Open Res       Date:  2020-03-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.